Isiokwu mbụ nke ngwaahịa mkpụrụ ndụ CARsgenCAR-T iji nweta mgbaghara zuru oke

Na Febụwarị 10, 2025, CARsgen Therapeutics kwupụtara na onye mbụ ejiri ọgwụgwọ allogeneic BCMA CAR-T gwọọ nke e mepụtara na ikpo okwu THANK-u Plus™, enwetala nzaghachi zuru oke (sCR) na obere ọrịa fọdụrụ (MRD) na nyocha ụbọchị nke 28. E mepụtara ikpo okwu THANK-u Plus™ n'ime ụlọ ọrụ ahụ, bụ teknụzụ allogeneic CAR-T ọhụrụ nke e mere iji merie ihe ịma aka ịnweta na ọgwụgwọ CAR-T.

Onye ọrịa ahụ, nke a chọpụtara na ọ nwere ọrịa myeloma relapsed/refractory multiple myeloma, ụdị IgA-λ (R-ISS Stage II), agafeela usoro ọgwụgwọ atọ nke njikọta yana transplantation sel hematopoietic autologous. Mgbe ọrịa ahụ gasịrị, a debanyere aha onye ọrịa ahụ na nnwale ahụike. Mgbe etinyere mkpụrụ ndụ CAR T na ọkwa kachasị ala dịka usoro ọgwụgwọ si dị, onye ọrịa ahụ nwetara ọrịa cytokine release syndrome (CRS) nke Grade 1, nke ejiri ọgwụ antipyretics na tocilizumab gwọọ nke ọma, onye ọrịa ahụ egosighikwa ọrịa neurotoxicity metụtara sel immune effector (ICANS) ma ọ bụ ihe omume ndị ọzọ metụtara CAR-T, nke na-egosi profaịlụ nchekwa dị mma n'ozuzu ya.

A na-emepụta ọgwụgwọ CAR-T a maka ọgwụgwọ nke ọrịa myeloma nke na-alaghachi azụ/na-adịghị agbanwe agbanwe (R/R MM) na ọrịa leukemia nke na-alaghachi azụ/na-adịghị agbanwe agbanwe (R/R PCL). A na-atụ anya mmelite data ndị ọzọ na ọkara nke abụọ nke afọ a.

Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.

Nọmba ekwentị: 4008803716

Email：myimmnet@163.com

Ntụaka

1.https://www.carsgen.com/cn/

2.https://www.prnasia.com/